At birth you already see pronounced neuroinflammation while the brain is still developing
A team at the University of Wisconsin–Madison has discovered that the neurological damage long associated with Down syndrome does not begin in adulthood, as decades of research assumed, but at birth itself — unfolding silently in the brain's most formative years. Published in Science, the finding reframes Down syndrome as a condition whose deepest wounds are struck before a child can speak, placing the possibility of intervention in a window far earlier, and far more urgent, than medicine had imagined. For the more than 90 percent of people with Down syndrome who will eventually develop Alzheimer's disease, this discovery is both a sobering reckoning and a fragile new hope.
- Neuroinflammation and molecular signatures of neurodegeneration are already present in Down syndrome brains at birth, decades before any cognitive symptoms appear — upending the field's foundational assumptions.
- The disruption is not confined to the extra copy of chromosome 21; gene dysregulation cascades across multiple chromosomes, destabilizing metabolism, inflammation, and cell death pathways simultaneously in the developing brain.
- All three major types of glial cells — the brain's own support network — are firing in pro-inflammatory patterns and amplifying each other's signals, creating what researchers describe as a compounding 'bad mixture' during the precise window when neurons are forming their most critical connections.
- Scientists do not yet know what triggers the initial cascade, and are now racing to identify whether the first signal originates before birth, in the womb itself.
- The urgency is sharpening: if the damage begins in the first three years of life, the window for therapeutic intervention is narrower than anyone previously understood, and the clock starts at birth.
Neuroscientists at the University of Wisconsin–Madison have published a finding in Science that fundamentally redraws the timeline of Down syndrome's neurological toll. For decades, researchers believed the cognitive decline that leads more than 90 percent of Down syndrome individuals toward Alzheimer's disease began in early adulthood. The new research reveals it begins at birth.
Led by assistant professor André Sousa, the team examined brain cells from the dorsolateral prefrontal cortex — a region central to thinking and working memory — in infants and very young children with Down syndrome. Even at birth, the brains showed pronounced neuroinflammation and the molecular signatures of neurodegeneration, unfolding precisely when neurons should be forming their foundational connections. Chronic inflammation during this window, the researchers warn, can compromise those processes in ways that reverberate for a lifetime.
What surprised the team was the breadth of the disruption. Though Down syndrome originates from a third copy of chromosome 21, the gene dysregulation they observed spread across multiple chromosomes — affecting pathways governing metabolism, inflammation, and cell death, while silencing genes needed for cells to mature and communicate. Graduate student and first author Ryan Risgaard described it as a network of dysfunction far wider than a single chromosome.
Driving the inflammation are glial cells, the brain's support structures, whose three major types were all showing pro-inflammatory activity and appeared to be amplifying one another's signals. Sousa's team does not yet know what triggers this cascade — it may originate even before birth — and they are now working to identify the first molecular domino to fall.
The stakes of that search are high. If the damage is already underway in infancy, the window for intervention is not in adulthood but in the earliest years of life, before the brain's architecture is set. The hope is that pinpointing these early mechanisms will make it possible to develop targeted therapies for infants — treatments that could interrupt the long, slow injury before it becomes irreversible.
A team of neuroscientists at the University of Wisconsin–Madison has discovered that the brain damage associated with Down syndrome begins not in middle age, when symptoms typically emerge, but at birth itself—during the most formative period of neural development. The finding, published in Science, fundamentally shifts how researchers understand the condition and when intervention might be possible.
Down syndrome occurs when a person is born with three copies of chromosome 21 instead of two. It is the most common genetic cause of intellectual disability. What makes the condition particularly cruel is its long arc: more than 90 percent of people with Down syndrome eventually develop Alzheimer's disease as adults. For decades, researchers assumed the neurological decline began in early adulthood, when cognitive symptoms first became noticeable. The new work suggests the process starts much earlier—in the first three years of life, when the brain is still actively building itself.
André Sousa, an assistant professor of neuroscience at UW–Madison who led the study, and his team examined brain cells from the dorsolateral prefrontal cortex, a region critical for thinking and working memory. What they found was striking: even in infants and very young children with Down syndrome, the brain was already showing signs of neuroinflammation—an abnormal immune response inside the brain—and the molecular signatures of neurodegeneration. "At birth you already see this very pronounced neuroinflammation and signatures of neurodegeneration while the brain is still developing," Sousa said. The discovery matters because the first few years of life are when neurons form connections with each other and brain cells mature. Inflammation during this window can disrupt these critical processes in ways that may echo for decades.
The researchers expected to find problems in genes located on chromosome 21, since that is the chromosome present in triplicate. Instead, they discovered something more complex. Gene expression was disrupted across multiple chromosomes, not just the extra copy of 21. Genes involved in metabolism, inflammation, and cell death were abnormally active. Meanwhile, genes necessary for cells to mature and communicate with one another were underactive. Ryan Risgaard, a graduate student in Sousa's lab and first author of the paper, described it as expanding the view beyond a single chromosome to a broader network of dysfunction. "The root is all in chromosome 21, but downstream, it does affect a lot of other chromosomes," Sousa explained.
The inflammation itself appears to be driven by glial cells—the brain's support cells. All three major types of glial cells showed pro-inflammatory patterns, and they appeared to be communicating with each other in ways that amplified the inflammatory response. This creates what Sousa called "a bad mixture" of neuroinflammation, altered metabolism, and cell death happening simultaneously in the developing brain. The timing is particularly significant. During early childhood, neurons are actively forming and pruning synapses—the connections that underlie learning and memory. Chronic inflammation during this period can damage these processes before they are even fully established.
The researchers do not yet know what triggers this inflammatory cascade. It may begin even before birth, in the womb. Sousa's team is now investigating whether the initial signal comes from microglia, astrocytes, or neurons themselves. Understanding the first domino to fall could open the door to intervention—potentially blocking or slowing the inflammatory process before it causes lasting damage. For a field that has long viewed Down syndrome as a condition that primarily manifests in adulthood, this reframing suggests that the window for prevention or early treatment may be far narrower and more urgent than previously understood. The hope is that identifying these early molecular changes will lead to specific drugs or therapies that could be given to infants and young children, before the brain's architecture is permanently altered.
Citas Notables
At birth you already see this very pronounced neuroinflammation and signatures of neurodegeneration while the brain is still developing.— André Sousa, assistant professor of neuroscience at UW–Madison
There's a loop here of neuroinflammation, altered metabolism, and apoptosis that all together create a bad mixture.— André Sousa
La Conversación del Hearth Otra perspectiva de la historia
So the study found inflammation in the brains of newborns with Down syndrome. But how do you even measure that in a baby who can't tell you anything is wrong?
They weren't studying living babies directly. They examined brain tissue samples from individuals with Down syndrome who were between birth and three years old, looking at the cells under a microscope and analyzing which genes were turned on or off. It's like reading the molecular diary of what was happening in those brains.
And they found inflammation already happening. But inflammation is normal—the immune system needs to do its job. What makes this inflammation a problem?
The issue is that it's chronic and it's happening during the exact moment when the brain is supposed to be building itself. When neurons are forming connections with each other, inflammation can interfere with that wiring. It's like trying to build a house while someone's setting small fires inside.
The study mentions that genes on other chromosomes are affected, not just chromosome 21. That seems to contradict the whole idea that Down syndrome is about having an extra copy of one chromosome.
It does seem contradictory at first. But think of chromosome 21 as the initial problem—the root cause. Having an extra copy throws off the balance of proteins in the cell. Those proteins then affect how other genes across the genome behave. So the extra chromosome is the spark, but the fire spreads everywhere.
What happens now? Do doctors start treating newborns with Down syndrome differently based on this?
Not yet. The researchers themselves say they don't know what's triggering the inflammation or how to stop it. This study is a map showing where the damage begins. The next phase is figuring out which lever to pull—which cell type, which gene, which pathway—to actually prevent it. That's years of work ahead.